Fresenius Kabi voluntarily recalls sodium acetate injection, USP, 400 mEq/100 mL, 100 mL fill in 100 mL vial, due to presence of particulate matter; products sold to wholesalers, distributors, hospitals, pharmacies between September 2020, November 2021

Sample article from our Health Care Sector

LAKE ZURICH, Illinois , March 10, 2022 (press release) –

Summary

Company Announcement Date:

March 07, 2022

FDA Publish Date:

March 07, 2022

Product Type:

Drugs

Reason for Announcement:

Due to the presence of particulate matter found in reserve and/or stability sample vials

Company Name:

Fresenius Kabi, USA

Brand Name:

Fresenius Kabi USA

Product Description:

Sodium Acetate Injection, USP, 400 mEq/100 mL (4 mEq/mL), 100 mL fill in a 100 mL vial

 

Company Announcement

Fresenius Kabi USA is voluntarily recalling seven lots of Sodium Acetate Injection, USP, 400 mEq/100 mL (4 mEq/mL), 100 mL fill in a 100 mL vial to the user level due to the presence of particulate matter found in reserve and/or stability sample vials. Microscopic and elemental analyses determined the presence of particulates composed of carbon and oxygen with varying amounts of iron and trace amounts of sodium, silicon, chromium, aluminum and cellulose.

https://s3.industryintel.com/imgxdoc/E5FF4A1843BA4B37B131AB8B83E4C0C6.png" style="width: 400px; height: 151px;" />

 

The administration of an injectable product that contains particulate matter may result in local irritation or swelling or infection in response to the foreign material.  If the particulate matter reaches the blood vessels it can travel to various organs and block blood vessels in the heart, lungs or brain which can cause stroke and even lead to death.  To date, no adverse event reports have been received for these recalled lots, which were produced and sold in 2020 and 2021.

Sodium Acetate Injection, USP is indicated as a source of sodium, for addition to large volume IV fluids to prevent or correct low blood sodium levels in patients with restricted or no oral intake. It is also useful as an additive for preparing specific IV fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. Listed below is a table of the recalled lots distributed nationwide to wholesalers, distributors, hospitals, and pharmacies between September 2020 and November 2021. An image of the product packaging is also included below. 

Product Name/Product size

NDC Number

Product Code

Batch Number

Expiration Date

First Ship Date

Last Ship Date

Sodium Acetate Injection, USP, 400 mEq/ 100 mL (4 mEq/mL), 100 mL fill in a 100 mL vial

63323-032-00

322100

6124193

05/2022

09/08/2020

12/22/2020

6124196

05/2022

11/16/2020

01/27/2021

6124226

05/2022

12/22/2020

03/22/2021

6124532

06/2022

01/27/2021

04/13/2021

6125333

12/2022

04/06/2021

06/01/2021

6125678

01/2023

06/23/2021

09/27/2021

6126846

08/2023

10/07/2021

11/17/2021

 

Fresenius Kabi is notifying its distributors and customers by letter and asking customers and distributors to check their stock immediately and to quarantine and discontinue the use and distribution of any affected product. Distributors should notify their customers and direct them to quarantine and discontinue distributing or dispensing the affected lots, and to return the product to Fresenius Kabi. The recall letter and response form are available at https://www.freseniusExternal Link Disclaimer-External Link Disclaimerkabi.com/us/pharmaceuticalExternal Link Disclaimer-External Link DisclaimerproductExternal Link Disclaimer-External Link DisclaimerupdatesExternal Link Disclaimer.External Link Disclaimer

Customers with questions regarding this recall may contact Fresenius Kabi at 1-866-716-2459 Monday through Friday, during the hours of 8:00 a.m. to 5:00 p.m. Central Time. Consumers should contact their physician or health care provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Complete and submit the report Online

Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Or, contact Fresenius Kabi at 1-800-551-7176, Monday through Friday, during the hours of 8:00 a.m. to 5:00 p.m. or via email at:  productcomplaint.USA@fresenius-kabi.com or adverse.events.USA@fresenius-kabi.com

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

 About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. For more information about Fresenius Kabi worldwide, please visit www.freseniusExternal Link Disclaimer-External Link Disclaimerkabi.comExternal Link Disclaimer.External Link Disclaimer 

###

Company Contact Information

Consumers:

Fresenius Kabi

 1-866-716-2459

Media:

Matt Kuhn

 (847) 550-5751

 matt.kuhn@fresenius-kabi.com

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Jason Irving
Jason Irving
- SVP Enterprise Solutions -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.